AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump

Key TakeawaysAbbVie warned Friday that sales of its blockbuster arthritis drug, Humira, will continue to lose market share to biosimilars.Revenue from Humira declined 35.9% in the first quarter, AbbVie reported.Despite the drop in Humira sales, AbbVie beat earnings and revenue forecasts in the quarter, and raised its full-year guidance.AbbVie shares were down nearly 5% in late trading Friday. Shares of AbbVie (ABBV) slumped Friday as the pharmaceutical firm warned of deeper declines in sales of its blockbus ...